Effects of Oxytocin Versus Promestriene on Genitourinary Syndrome: a Pilot, Prospective, Randomized, Double-blind Study

Overview

Journal Clinics (Sao Paulo)

Publisher Elsevier

Specialty General Medicine

Date 2022 Oct 4

PMID 36194923

Authors

Liani Patricia Andrade Santos

Claudio Emilio Bonduki

Rita de Cassia de Maio Dardes

Thais Heinke

Marisa Teresinha Patriarca

Affiliations

Soon will be listed here.

Abstract

Objectives: In this pilot, prospective, randomized, double-blind study, the authors compared the efficacy of oxytocin with promestriene in improving vaginal atrophy of Genitourinary Syndrome of Menopause (GSM).

Methods: A total of 51 postmenopausal women with symptoms of GSM were evaluated. They were randomized into two groups: oxytocin (25 patients) and promestriene (26 patients) and were evaluated before and after 90 days of treatment; the evaluation was based on the domains of the Female Sexual Function Index (FSFI) (lubrication, satisfaction, and pain during sexual intercourse), clinical visual examination, and vaginal wall thickness.

Results: After the use of the medications, both groups showed significant improvement in the three evaluated FSFI domains (p < 0.05) and there was no significant difference between the groups (p > 0.05). On clinical examination, the medications improved all the evaluated parameters but without statistical significance (p > 0.05). The evaluation of the thickness of the vaginal epithelium showed that both treatments led to increase in the vaginal epithelium (p < 0.05); however, the efficacy of promestriene was higher than that of oxytocin (p < 0.05).

Conclusions: Both medications were effective, however, studies with larger samples and longer follow-ups are needed to confirm the clinical applicability.

Citing Articles

Vulvovaginal Atrophy Following Treatment for Oncogynecologic Pathologies: Etiology, Epidemiology, Diagnosis, and Treatment Options.

Narutyte R, Zukiene G, Bartkeviciene D Medicina (Kaunas). 2024; 60(10).

PMID: 39459371 PMC: 11509822. DOI: 10.3390/medicina60101584.

References

. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017; 24(7):728-753. DOI: 10.1097/GME.0000000000000921. View

Furuya K, Mizumoto Y, Makimura N, Mitsui C, Murakami M, Tokuoka S . A novel biological aspect of ovarian oxytocin: gene expression of oxytocin and oxytocin receptor in cumulus/luteal cells and the effect of oxytocin on embryogenesis in fertilized oocytes. Adv Exp Med Biol. 1995; 395:523-8. View

Gimpl G, Fahrenholz F . The oxytocin receptor system: structure, function, and regulation. Physiol Rev. 2001; 81(2):629-83. DOI: 10.1152/physrev.2001.81.2.629. View

Kallak T, Uvnas-Moberg K . Oxytocin stimulates cell proliferation in vaginal cell line Vk2E6E7. Post Reprod Health. 2017; 23(1):6-12. DOI: 10.1177/2053369117693148. View

Lethaby A, Ayeleke R, Roberts H . Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2016; (8):CD001500. PMC: 7076628. DOI: 10.1002/14651858.CD001500.pub3. View

Behnia-Willison F, Sarraf S, Miller J, Mohamadi B, Care A, Lam A . Safety and long-term efficacy of fractional CO laser treatment in women suffering from genitourinary syndrome of menopause. Eur J Obstet Gynecol Reprod Biol. 2017; 213:39-44. DOI: 10.1016/j.ejogrb.2017.03.036. View

Al-Saqi S, Jonasson A, Naessen T, Uvnas-Moberg K . Oxytocin improves cytological and histological profiles of vaginal atrophy in postmenopausal women. Post Reprod Health. 2016; 22(1):25-33. DOI: 10.1177/2053369116629042. View

Utian W . Biosynthesis and physiologic effects of estrogen and pathophysiologic effects of estrogen deficiency: a review. Am J Obstet Gynecol. 1989; 161(6 Pt 2):1828-31. DOI: 10.1016/s0002-9378(89)80002-x. View

Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R . The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000; 26(2):191-208. DOI: 10.1080/009262300278597. View

10.

Al-Saqi S, Uvnas-Moberg K, Jonasson A . Intravaginally applied oxytocin improves post-menopausal vaginal atrophy. Post Reprod Health. 2015; 21(3):88-97. PMC: 4566058. DOI: 10.1177/2053369115577328. View

11.

Simon J, Goldstein I, Kim N, Davis S, Kellogg-Spadt S, Lowenstein L . The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review. Menopause. 2018; 25(7):837-847. DOI: 10.1097/GME.0000000000001138. View

12.

Ghorbani Z, Mirghafourvand M . The efficacy and safety of intravaginal oxytocin on vaginal atrophy: A systematic review. Post Reprod Health. 2020; 27(1):30-41. DOI: 10.1177/2053369120946645. View

13.

Jonasson A, Edwall L, Uvnas-Moberg K . Topical oxytocin reverses vaginal atrophy in postmenopausal women: a double-blind randomized pilot study. Menopause Int. 2011; 17(4):120-5. DOI: 10.1258/mi.2011.011030. View

14.

Zerbinati N, Serati M, Origoni M, Candiani M, Iannitti T, Salvatore S . Microscopic and ultrastructural modifications of postmenopausal atrophic vaginal mucosa after fractional carbon dioxide laser treatment. Lasers Med Sci. 2014; 30(1):429-36. DOI: 10.1007/s10103-014-1677-2. View

15.

Pup L, di Francia R, Cavaliere C, Facchini G, Giorda G, de Paoli P . Promestriene, a specific topic estrogen. Review of 40 years of vaginal atrophy treatment: is it safe even in cancer patients?. Anticancer Drugs. 2013; 24(10):989-98. DOI: 10.1097/CAD.0b013e328365288e. View

16.

Salvatore S, Nappi R, Zerbinati N, Calligaro A, Ferrero S, Origoni M . A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study. Climacteric. 2014; 17(4):363-9. DOI: 10.3109/13697137.2014.899347. View

17.

Nielsen E, Al-Saqi S, Jonasson A, Uvnas-Moberg K . Population Pharmacokinetic Analysis of Vaginally and Intravenously Administered Oxytocin in Postmenopausal Women. J Clin Pharmacol. 2017; 57(12):1573-1581. DOI: 10.1002/jcph.961. View

18.

Torky H, Taha A, Marie H, El-Desouky E, Raslan O, Moussa A . Role of topical oxytocin in improving vaginal atrophy in postmenopausal women: a randomized, controlled trial. Climacteric. 2018; 21(2):174-178. DOI: 10.1080/13697137.2017.1421924. View

19.

Gandhi J, Chen A, Dagur G, Suh Y, Smith N, Cali B . Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. Am J Obstet Gynecol. 2016; 215(6):704-711. DOI: 10.1016/j.ajog.2016.07.045. View

20.

Steele N, Ledbetter C, Bernier F . Genitourinary Syndrome Of Menopause and Vaginal Estrogen Use. Urol Nurs. 2016; 36(2):59-65, 71. View